Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
US9265764B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 27, 2010 |
| Grant date | Feb 23, 2016 |
| Priority date | — |
| Expiry date | Apr 2, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.